S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
How to Invest in AI's Fast-Growing Market (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
How to Invest in AI's Fast-Growing Market (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
The Graphite Shortage Story You're Not Being Told (Ad)
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
How to Invest in Specialty Retail Stores
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
How to Invest in AI's Fast-Growing Market (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
How to Invest in AI's Fast-Growing Market (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
The Graphite Shortage Story You're Not Being Told (Ad)
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
How to Invest in Specialty Retail Stores
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
How to Invest in AI's Fast-Growing Market (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
How to Invest in AI's Fast-Growing Market (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
The Graphite Shortage Story You're Not Being Told (Ad)
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
How to Invest in Specialty Retail Stores
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
How to Invest in AI's Fast-Growing Market (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
How to Invest in AI's Fast-Growing Market (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
The Graphite Shortage Story You're Not Being Told (Ad)
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
How to Invest in Specialty Retail Stores
NASDAQ:SLNO

Soleno Therapeutics (SLNO) Stock Forecast, Price & News

$5.88
+0.61 (+11.57%)
(As of 06/1/2023 ET)
Compare
Today's Range
$5.25
$5.88
50-Day Range
$2.14
$5.88
52-Week Range
$0.85
$5.88
Volume
131,715 shs
Average Volume
188,486 shs
Market Capitalization
$48.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Soleno Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
36.1% Upside
$8.00 Price Target
Short Interest
Healthy
1.25% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
1.19mentions of Soleno Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Acquiring Shares
$647,150 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.71) to ($0.47) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

Medical Sector

305th out of 1,980 stocks

Electromedical Equipment Industry

5th out of 46 stocks


SLNO stock logo

About Soleno Therapeutics (NASDAQ:SLNO) Stock

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Receive SLNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SLNO Stock News Headlines

How to Invest in AI's Fast-Growing Market
The AI market stands at $160 billion in 2023. Estimates are the AI market will grow 20-fold to $1.8 TRILLION by 2030. One little-known company is looking to win big with a new network technology no one else has. AI could explode... and soon.
The Real Problem With "Made in America" Lithium
Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.
SLNO Soleno Therapeutics, Inc.
7 Top Short-Squeeze Candidates to Watch in February
Oppenheimer Reaffirms Their Buy Rating on Soleno Therapeutics (SLNO)
SLNO.OQ - | Stock Price & Latest News | Reuters
Why Is Soleno Therapeutics (SLNO) Stock Up 130% Today?
See More Headlines

SLNO Price History

SLNO Company Calendar

Last Earnings
3/21/2023
Today
6/01/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SLNO
Employees
17
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+36.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-24,070,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.32 per share

Miscellaneous

Free Float
6,233,000
Market Cap
$48.04 million
Optionable
Not Optionable
Beta
0.22

Key Executives

  • Anish Bhatnagar
    President, Chief Executive & Operating Officer
  • James H. MackanessJames H. Mackaness
    Chief Financial Officer
  • Kristen Yen
    Vice President-Clinical Operations
  • Michael Woloschak
    Vice President-Clinical Development
  • Harish Ravivarapu
    Vice President-Technical Operations













SLNO Stock - Frequently Asked Questions

Should I buy or sell Soleno Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SLNO shares.
View SLNO analyst ratings
or view top-rated stocks.

What is Soleno Therapeutics' stock price forecast for 2023?

1 Wall Street analysts have issued 12 month target prices for Soleno Therapeutics' shares. Their SLNO share price forecasts range from $8.00 to $8.00. On average, they predict the company's share price to reach $8.00 in the next year. This suggests a possible upside of 36.1% from the stock's current price.
View analysts price targets for SLNO
or view top-rated stocks among Wall Street analysts.

How have SLNO shares performed in 2023?

Soleno Therapeutics' stock was trading at $1.98 on January 1st, 2023. Since then, SLNO shares have increased by 197.0% and is now trading at $5.88.
View the best growth stocks for 2023 here
.

When is Soleno Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our SLNO earnings forecast
.

How were Soleno Therapeutics' earnings last quarter?

Soleno Therapeutics, Inc. (NASDAQ:SLNO) posted its earnings results on Tuesday, March, 21st. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.76) by $0.18.

When did Soleno Therapeutics' stock split?

Soleno Therapeutics's stock reverse split on the morning of Friday, August 26th 2022. The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Soleno Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), OPKO Health (OPK), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Miragen Therapeutics (MGEN), Vaxart (VXRT), Dynavax Technologies (DVAX) and TherapeuticsMD (TXMD).

What is Soleno Therapeutics' stock symbol?

Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."

Who are Soleno Therapeutics' major shareholders?

Soleno Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Carlyle Group Inc. (14.71%), Renaissance Technologies LLC (0.94%), JPMorgan Chase & Co. (0.86%) and Dimensional Fund Advisors LP (0.37%). Insiders that own company stock include Bhatnagar Anish, Jack W Schuler, James H Mackaness, Perceptive Advisors Llc and William G Harris.
View institutional ownership trends
.

How do I buy shares of Soleno Therapeutics?

Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Soleno Therapeutics' stock price today?

One share of SLNO stock can currently be purchased for approximately $5.88.

How much money does Soleno Therapeutics make?

Soleno Therapeutics (NASDAQ:SLNO) has a market capitalization of $48.04 million. The company earns $-24,070,000.00 in net income (profit) each year or ($3.1196) on an earnings per share basis.

How can I contact Soleno Therapeutics?

Soleno Therapeutics' mailing address is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. The official website for the company is www.soleno.life. The company can be reached via phone at (650) 213-8444, via email at ir@soleno.life, or via fax at 650-213-8383.

This page (NASDAQ:SLNO) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -